Spontaneous presence of FOXO3-specific T cells in cancer patients

OncoImmunology

Volumn 3, Issue 8, 2014, Pages

  Larsen, Stine Kiaer ^a   Ahmad, Shamaila Munir ^a   Idorn, Manja ^a   Met, Özcan ^a   Martinenaite, Evelina ^a   Svane, Inge Marie ^a   Straten, Per Thor ^a   Andersen, Mads Hald ^a  

^a Mental Health Center Glostrup   (Denmark)

Author keywords

Antigens; CTL; FOXO3; Immune regulation; Tumor associated dendritic cells

Indexed keywords

CANCER GROWTH FACTOR; EPITOPE; GAMMA INTERFERON; HLA A2 ANTIGEN; IMMUNOGLOBULIN G; PROGRAMMED DEATH 1 LIGAND 1; PROSTAGLANDIN E2; SMALL INTERFERING RNA; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FKHRL1; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR;

AMINO ACID SEQUENCE; ARTICLE; BREAST CANCER; CANCER PATIENT; CD8+ T LYMPHOCYTE; COLON CANCER; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DENDRITIC CELL; DOWN REGULATION; ELECTROPORATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; GENE SILENCING; GENETIC TRANSFECTION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOFLUORESCENCE; IMMUNOGENICITY; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; MELANOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; RENAL CELL CARCINOMA; T LYMPHOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; WESTERN BLOTTING;

EID: 85043225627     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/21624011.2014.953411     Document Type: Article

References (49)

1. Nurieva RI, Liu X, Dong C. Molecular mechanisms of T-cell tolerance. Immunol Rev 2011; 241:133-44; PMID:21488895; http://dx.doi.org/10.1111/j.1600-065X.2011.01012.x
2. Hurwitz AA, Watkins SK. Immune suppression in the tumor microenvironment: a role for dendritic cell-mediated tolerization of T cells. Cancer Immunol Immunother 2012; 61:289-93; PMID:22237887; http://dx.doi.org/10.1007/s00262-011-1181-5
3. Zhu Z, Singh V, Watkins SK, Bronte V, Shoe JL, Feigenbaum L, Hurwitz AA. High-avidity T cells are preferentially tolerized in the tumor microenvironment. Cancer Res 2013; 73:595-604; PMID:23204239; http://dx.doi.org/10.1158/0008-5472.CAN-12-1123
4. Muller AJ, DuHadaway JB, Chang MY, Ramalingam A, Sutanto-Ward E, Boulden J, Soler AP, Mandik-Nayak L, Gilmour SK, Prendergast GC. Non-hemato-poietic expression of IDO is integrally required for inflammatory tumor promotion. Cancer Immunol Immunother 2010; 59:1655-63; PMID:20640572; http://dx.doi.org/10.1007/s00262-010-0891-4
5. Pletinckx K, Dohler A, Pavlovic V, Lutz MB. Role of dendritic cell maturity/costimulation for generation, homeostasis, and suppressive activity of regulatory T cells. Front Immunol 2011; 2:1-16; PMID:22566792; http://dx.doi.org/10.3389/fimmu.2011.00039
6. Watkins SK, Zhu Z, Riboldi E, Shafer-Weaver KA, Sta-gliano KE, Sklavos MM, Ambs S, Yagita H, Hurwitz AA. FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostatecancer.JClin Invest 2011; 121:1361-72; PMID:21436588; http://dx. doi.org/10.1172/JCI44325
7. Watkins SK, Hurwitz AA. FOXO3: A master switch for regulating tolerance and immunity in dendritic cells. Oncoimmunology 2012; 1:252-4; PMID:22720261; http://dx.doi.org/10.4161/onci.1.2.18241
8. Dejean AS, Beisner DR, Ch’en IL, Kerdiles YM, Babour A, Arden KC, Castrillon DH, DePinho RA, Hedrick SM. Transcription factor Foxo3 controls the magnitude of T cell immune responses by modulating the function of dendritic cells. Nat Immunol 2009; 10:504-13; PMID: 19363483; http://dx.doi.org/10.1038/ni.1729
9. Shafer-Weaver KA, Watkins SK, Anderson MJ, Draper LJ, Malyguine A, Alvord WG, Greenberg NM, Hurwitz AA. Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells. Cancer Res 2009; 69:6256-64; PMID:19622771; http://dx.doi.org/10.1158/0008-5472.CAN-08-4516
10. Paik JH, Kollipara R, Chu G, Ji H, Xiao Y, Ding Z, Horner JW, Carrasco DR, Jiang S, Gilliland DG, et al. FoxOs are lineage-restricted redundant tumor suppres-sors and regulate endothelial cell homeostasis. Cell 2007; 128:309-23; PMID:17254969; http://dx.doi. org/10.1016/j.cell.2006.12.029
11. Kops GJ, Dansen TB, Polderman PE, Saarloos I, Wirtz KW, Coffer PJ, Huang TT, Bos JL, Medema RH, Bur-gering BM. Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature 2002; 419:316-21; PMID:12239572; http://dx.doi. org/10.1038/nature01036
12. Yu C, Zhang Z, Liao W, Zhao X, Liu L, Wu Y, Liu Z, Li Y, Zhong Y, Chen K, et al. The tumor-suppressor gene Nkx2.8 suppresses bladder cancer proliferation through upregulation of FOXO3a and inhibition of the MEK/ERK signaling pathway. Carcinogenesis 2012; 33:678-86; PMID:22223847; http://dx.doi.org/10.1093/carcin/bgr321
13. Storz P, Doppler H, Copland JA, Simpson KJ, Toker A. FOXO3a promotes tumor cell invasion through the induction of matrix metalloproteinases. Mol Cell Biol 2009; 29:4906-17; PMID:19564415; http://dx.doi. org/10.1128/MCB.00077-09
14. Hu MC, Lee DF, Xia W, Golfman LS, Ou-Yang F, Yang JY, Zou Y, Bao S, Hanada N, Saso H, et al. Ikap-paB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 2004; 117:225-37; PMID:15084260; http://dx.doi.org/10.1016/S0092-8674(04)00302-2
15. Pamer E, Cresswell P. Mechanisms of MHC class I– restricted antigen processing. Annu Rev Immunol 1998; 16:323-58; PMID:9597133; http://dx.doi.org/10.1146/annurev.immunol.16.1.323
16. Larsen SK, Munir S, Woetmann A, Froesig TM, Odum N, Svane IM, Becker JC, Andersen MH. Functional characterization of Foxp3-specific spontaneous immune responses. Leukemia 2013; 27:2332-40; PMID:23812418; http://dx.doi.org/10.1038/leu.2013.196
17. Rammensee HG, Falk K, Roetzschke O. MHC molecules as peptide receptors. Curr Biol 1995; 5:35-44; PMID:7697344; http://dx.doi.org/10.1016/S0960-9822(95)00011-X
18. Andersen MH, Pedersen LO, Becker JC, Thorstraten P. Identification of a Cytotoxic T Lymphocyte Response to the Apoptose Inhibitor Protein Survivin in Cancer Patients. Cancer Res 2001; 61:869-72; PMID:11221872
19. Scheibenbogen C, Sun Y, Keilholz U, Song M, Stevanovic S, Asemissen AM, Nagorsen D, Thiel E, Rammensee HG, Schadendorf D. Identification of known and novel immu-nogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment. Int J Cancer 2002; 20; 98:409-14; PMID:11920592; http://dx.doi.org/10.1002/ijc.10205
20. Herr W, Ranieri E, Gambotto A, Kierstead LS, Amo-scato AA, Gesualdo L, Storkus WJ. Identification of naturally processed and HLA-presented Epstein-Barr virus peptides recognized by CD4(+) or CD8(+) T lymphocytes from human blood. Proc Natl Acad Sci U S A 1999; 96:12033-38; PMID:10518571; http://dx. doi.org/10.1073/pnas.96.21.12033
21. Andersen MH, Fensterle J, Ugurel S, Reker S, Houben R, Guldberg P, Berger TG, Schadendorf D, Trefzer U, Bröocker EB, et al. Immunogenicity of constitutively active V599EBRaf. Cancer Res 2004; 64:5456-60; PMID:15289355; http://dx.doi.org/10.1158/0008-5472.CAN-04-0937
22. -2 in cancer patients. Blood 2005; 15:728-34; PMID:15367432; http://dx.doi.org/10.1182/blood-2004-07-2548
23. Wenandy L, Sorensen RB, Sengelov L, Svane IM, Thor SP, Andersen MH. The immunogenicity of the hTERT540–548 peptide in cancer. Clin Cancer Res 2008; 14:4-7; PMID:18172245; http://dx.doi.org/10.1158/1078-0432.CCR-07-4590
24. Sorensen RB, Berge-Hansen L, Junker N, Hansen CA, Hadrup SR, Schumacher TN, Svane IM, Becker JC, thor Straten P, Andersen MH. The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase. PLoS One 2009; 4:e6910; PMID:19738905; http://dx.doi.org/10.1371/journal. pone.0006910
25. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, Roederer M, Koup RA. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003; 281:65-78; PMID:14580882; http://dx.doi.org/10.1016/S0022-1759(03)00265-5
26. Birkenkamp KU, Essafi A, vanderVos KE, Hui RC, Holstege F, Koenderman L, Lam EW, Coffer PJ. FOXO3a induces differentiation of Bcr-Abl-transformed cells through transcriptional down-regulation of Id1. J Biol Chem 2007; 282:2211-20; PMID:17132628; http://dx.doi.org/10.1074/jbc. M606669200
27. Munir S, Andersen GH, Met O, Donia M, Frosig TM, Larsen SK, Klausen TW, Svane IM, Andersen MH. HLA-restricted cytotoxic T cells that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients. Cancer Research 2013; 73:1674-776; PMID:23328583; http://dx.doi.org/10.1158/0008-5472.CAN-12-3507
28. Yin L, Huang L, Kufe D. MUC1 oncoprotein activates the FOXO3a transcription factor in a survival response to oxidative stress. J Biol Chem 2004; 279:45721-7; PMID:15322085; http://dx.doi.org/10.1074/jbc. M408027200
29. Chen J, Gomes AR, Monteiro LJ, Wong SY, Wu LH, Ng TT, Karadedou CT, Millour J, Ip YC, Cheung YN, et al. Constitutively nuclear FOXO3a localization predicts poor survival and promotes Akt phosphoryla-tion in breast cancer. PLoS One 2010; 20:e12293; PMID:20808831; http://dx.doi.org/10.1371/journal. pone.0012293
30. Qi W, Weber CR, Wasland K, Roy H, Wali R, Joshi S, Savkovic SD. Tumor suppressor FOXO3 mediates signals from the EGF receptor to regulate proliferation of colonic cells. Am J Physiol Gastrointest Liver Physiol 2011; 300:G264-72; PMID:21109589; http://dx.doi. org/10.1152/ajpgi.00416.2010
31. Keilholz U, Weber J, Finke JH, Gabrilovich DI, Kast WM, Disis ML, Kirkwood JM, Scheibenbogen C, Schlom J, Maino VC, et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 2002; 25:97-138; PMID:12074049; http://dx. doi.org/10.1097/00002371-200203000-00001
32. Lee JC, Espeli M, Anderson CA, Linterman MA, Pocock JM, Williams NJ, Roberts R, Viatte S, Fu B, Peshu N, et al. Human SNP links differential outcomes in inflammatory and infectious disease to a FOXO3-regulated pathway. Cell 2013; 155:57-69; PMID:24035192; http://dx.doi.org/10.1016/j. cell.2013.08.034
33. Gnjatic S, Atanackovic D, Matsuo M, Jager E, Lee SY, Valmori D, Chen YT, Ritter G, Knuth A, Old LJ. Cross-presentation of HLA class I epitopes from exogenous NY-ESO-1 polypeptides by nonprofessional APCs. J Immunol 2003; 170:1191-96; PMID:12538675; http://dx.doi.org/10.4049/jimmunol. 170.3.1191
34. Nair S, Boczkowski D, Fassnacht M, Pisetsky D, Gilboa E. Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. Cancer Res 2007; 67:371-80; PMID: 17210720; http://dx.doi.org/10.1158/0008-5472. CAN-06-2903
35. Sorensen RB, Hadrup SR, Svane IM, Hjortso MC, thor Straten P, Andersen MH. Indoleamine 2,3-dioxy-genase specific, cytotoxic T cells as immune regulators. Blood 2011; 117:2200-10; PMID:21079151; http://dx.doi.org/10.1182/blood-2010-06-288498
36. Sorensen RB, Kollgaard T, Andersen RS, van den Berg JH, Svane IM, thor Straten P, Andersen MH. Spontaneous cytotoxic T-Cell reactivity against indoleamine 2,3-dioxygenase-2. Cancer Res 2011; 71:2038-44; PMID:21406395; http://dx.doi.org/10.1158/0008-5472. CAN-10-3403
37. Munir S, Andersen GH, Woetmann A, Odum N, Becker JC, Andersen MH. Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells. Leukemia 2013; 27:2251-53; PMID: 23660624; http://dx.doi.org/10.1038/leu.2013.118
38. Denning DP, Hatch V, Horvitz HR. Programmed elimination of cells by caspase-independent cell extrusion in C. elegans. Nature 2012; 488:226-30; PMID:22801495; http://dx.doi.org/10.1038/nature11240
39. Feig C, Peter ME. How apoptosis got the immune system in shape. Eur J Immunol 2007; 37:61-70; PMID:17972347; http://dx.doi.org/10.1002/eji. 200737462
40. Maiese K, Hou J, Chong ZZ, Shang YC. A fork in the path: developing therapeutic inroads with FoxO proteins. Oxid Med Cell Longev 2009; 2:119-29; PMID:20592766; http://dx.doi.org/10.4161/oxim.2. 3.8916
41. Lappas M, Lim R, Riley C, Menon R, Permezel M. Expression and localisation of FoxO3 and FoxO4 in human placenta and fetal membranes. Placenta 2010; 31:1043-50; PMID:20934750; http://dx.doi.org/10.1016/j.placenta.2010.09.009
42. Snoeks L, Weber CR, Wasland K, Turner JR, Vainder C, Qi W, Savkovic SD. Tumor suppressor FOXO3 participates in the regulation of intestinal inflammation. Lab Invest 2009; 89:1053-62; PMID:19636295; http://dx.doi.org/10.1038/labinvest.2009.66
43. McCutcheon M, Wehner N, Wensky A, Kushner M, Doan S, Hsiao L, Calabresi P, Ha T, Tran TV, Tate KM, et al. A sensitive ELISPOT assay to detect low-fre-quency human T lymphocytes. J Immunol Methods 1997; 210:149-66; PMID:9520298; http://dx.doi.org/10.1016/S0022-1759(97)00182-8
44. Moodie Z, Price L, Janetzki S, Britten CM. Response determination criteria for ELISPOT: toward a standard that can be applied across laboratories. Methods Mol Biol 2012; 792:185-96; PMID:21956511; http://dx. doi.org/10.1007/978-1-61779-325-7_15
45. Toebes M, Coccoris M, Bins A, Rodenko B, Gomez R, Nieuwkoop NJ, van de Kasteele W, Rimmelzwaan GF, Haanen JB, Ovaa H, et al. Design and use of conditional MHC class I ligands. Nat Med 2006; 12:246-51; PMID:16462803; http://dx.doi.org/10.1038/nm1360
46. Andersen MH, Bonfill JE, Neisig A, Arsequell G, Son-dergaard I, Valencia G, Neefjes J, Zeuthen J, Elliott T, Haurum JS. Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL. J Immunol 1999; 163:3812-8; PMID:10490979
47. Pawelec G, Marsh SG. ESTDAB: a collection of immunologically characterised melanoma cell lines and searchable databank. Cancer Immunol Immunother 2006; 55:623-7; PMID:16421722; http://dx.doi.org/10.1007/s00262-005-0117-3
48. Berke Z, Andersen MH, Pedersen M, Fugger L, Zeuthen J, Haurum JS. Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules. Leukemia 2000; 14:419-26; PMID:10720136; http://dx.doi. org/10.1038/sj.leu.2401703
49. Met O, Balslev E, Flyger H, Svane IM. High immuno-genic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer. Breast Cancer Res Treat 2011; 125:395-406; PMID:20336365; http://dx.doi.org/10.1007/s10549-010-0844-9